Results 21 to 30 of about 4,657,009 (154)
SAGE Open Medicine, 2023 Objectives: Hip fractures represent a prevalent geriatric cause of morbidity and mortality. The presence of multiple comorbidities requiring the use of an anticoagulant or antiplatelet medication adds complexity to management and influences outcomes ...
Asheesh R Elete +4 more
doaj +1 more source
Potential of anticoagulant therapy in cardiology practice for thrombocytopenia. Literature review
Российский кардиологический журнал, 2023 The review article discusses the issues of anticoagulant therapy in cardiovascular patients with thrombocytopenia (TP), gives the concept of ethylenediaminetetraacetic acidand heparin-induced TP.
K. G. Pereverzeva +2 more
doaj +1 more source
Drug Interactions Affecting Oral Anticoagulant Use
, 2022 Oral anticoagulants (OACs) are medications commonly used in patients with atrial fibrillation and other cardiovascular conditions. Both warfarin and direct oral anticoagulants are susceptible to drug-drug interactions (DDIs).
Dukes, Jonathan +30 more
core +1 more source
Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline Recommendations [PDF]
, 2022 This cohort study evaluates stroke and major bleeding rates before and after switching from warfarin to a direct oral anticoagulant (DOAC) in patients grouped by pre-switch time-in-therapeutic range guideline ...
Barnes, Geoffrey D. +14 more
core +1 more source
The risk of bleeding minimization with direct oral anticoagulants
Атеротромбоз, 2021 This review is devoted to the safety issues of anticoagulant therapy prescribed for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Direct oral anticoagulants are considered worldwide in accordance with the guidelines
Т. N. Novikova
doaj +1 more source
The new, direct, target-specific oral anticoagulants
Journal of Applied Hematology, 2015 In recent years, numerous alternatives to VKAs have been developed, the first competitors to warfarin are the novel oral anticoagulants (NOAC) or better referred to as Direct Oral Anti-Coagulant (DOAC) or Target Specific Oral Anti-coagulant (TSOAC ...
Nevine A Kassim
doaj +1 more source
Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]
, 2014 Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ +5 more
core +1 more source
The new way of Dabigatran reversal – Idarucizumab
Journal of Education, Health and Sport, 2019 Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban.
Erwin Ciechański +3 more
doaj +3 more sources
No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke [PDF]
, 2012 Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Ferdinand Bohmann +27 more
core +2 more sources
Bleeding on oral anticoagulants: overview of reversal strategies
Swiss Medical Weekly, 2023 Oral anticoagulants (antivitamin K, direct oral anticoagulants) are routinely prescribed for the prevention or treatment of thromboembolic events, and many patients are now on long-term anticoagulant therapy.
Mauro Foletti +5 more
doaj +1 more source